Cosentyx (Secukinumab) Denied: Appealing AS, PsA, and Plaque Psoriasis Denials

Cosentyx (secukinumab) is an IL-17A inhibitor FDA-approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and enthesitis-related arthritis in pediatric patients. It is frequently a first-line biologic recommendation for spondyloarthritis given its strong evidence in axial disease, and a preferred option for psoriasis patients with comorbid psoriatic arthritis. Despite this, insurance denials are common and follow predictable patterns.

Common Reasons Cosentyx Is Denied

NSAID failure requirement. For ankylosing spondylitis and nr-axSpA, most insurance plans require documented failure of at least two NSAIDs at full anti-inflammatory doses for at least 4 weeks each before approving a biologic. This is a strict step therapy requirement. Denials frequently occur when:

• Only one NSAID was documented
• Duration of NSAID use was not clearly stated
• NSAID was stopped for GI intolerance rather than inadequate response (though intolerance often qualifies for bypass)

DMARD failure for PsA. For psoriatic arthritis, insurers usually require trial of at least one conventional DMARD (typically methotrexate) before a biologic is approved. Some plans also require prior TNF inhibitor failure before an IL-17 inhibitor is covered.

Severity documentation gaps. For plaque psoriasis, "moderate-to-severe" must be objectively documented. For axial spondyloarthritis, disease activity should be captured with BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) or ASDAS scores. A BASDAI ≥ 4 is commonly cited in clinical guidelines as indicative of active, inadequately controlled disease.

Confusion between AS and nr-axSpA. Non-radiographic axial spondyloarthritis was added as a separate Cosentyx indication in 2021. Some insurer coverage policies have not been updated to reflect nr-axSpA specifically and deny claiming the diagnosis doesn't match the covered indication. This is an easy denial to overturn with documentation of the correct ICD-10 code (M45.x for AS; M46.x for nr-axSpA) and supporting MRI evidence of sacroiliac joint inflammation.

NSAID Failure: How to Document It Properly

The most common reason ankylosing spondylitis patients are denied Cosentyx is inadequate documentation of NSAID failure. Here is what the appeal letter should include:

• Specific NSAID names (naproxen 500 mg BID, indomethacin 50 mg TID, celecoxib 200 mg BID)
• Duration of each trial (ideally 4 weeks at maximum tolerated dose)
• Reason for failure: inadequate pain and stiffness control, intolerance, or contraindication
• Documentation that GI, cardiovascular, or renal contraindications prevented adequate NSAID use if relevant

If long-term NSAID use is contraindicated due to history of peptic ulcer disease, chronic kidney disease, anticoagulant use, or cardiovascular risk, these medical contraindications explicitly justify bypassing NSAID step therapy entirely.

Comparing Cosentyx to Other Biologics in the Appeal

If the insurer is pushing a TNF inhibitor (Humira, Enbrel) as the preferred first-line biologic before Cosentyx, your prescriber's appeal letter should address:

• For AS patients with predominantly axial disease, IL-17 inhibitors like Cosentyx have demonstrated comparable or superior spinal inflammation control in head-to-head and network meta-analysis data
• For psoriatic arthritis with significant skin involvement, Cosentyx addresses both joint and skin components with a single mechanism
• For patients with inflammatory bowel disease comorbidity, this is an important exception: IL-17 inhibitors are contraindicated or cautioned in IBD. If your patient has Crohn's or UC, document this clearly and redirect the appeal toward TNF or IL-23 inhibitors instead

The Pediatric Enthesitis-Related Arthritis Indication

For parents appealing Cosentyx for a child with enthesitis-related arthritis (a subtype of juvenile idiopathic arthritis), the pathway requires documentation of inadequate NSAID response and often DMARD failure. Pediatric rheumatologist letters carry significant weight in these appeals, and citing the specific pediatric trial data (JUNIPSA trial) strengthens the medical necessity argument.

Fight Back With ClaimBack

Whether you are appealing a Cosentyx denial for ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis, the key is detailed documentation of your prior treatment history and current disease activity. ClaimBack helps you build that case precisely.

Start your Cosentyx appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?